Relapsing Nail Fibrokeratoma: A Case Report on a Teenager

The document reports on a randomized controlled evaluator blinded study comparing the efficacy, safety, and tolerability of dutasteride versus finasteride in men with androgenetic alopecia (AGA). Ninety men aged 18-40 were randomized to receive either 0.5 mg dutasteride or 1 mg finasteride for 24 weeks. The study found that dutasteride was significantly more effective than finasteride in increasing total and thick hair count and decreasing thin hair count over the target area after 24 weeks. Both drugs had a similar side effect profile, with sexual dysfunction being the most common reversible side effect. The study concluded that dutasteride is more efficacious than finasteride with comparable adverse events, although the study was limited to a 6-month duration and had no commercial support. Additionally, the document includes a case report of a 14-year-old female with relapsing nail fibrokeratoma, which is a rare occurrence since this benign tumor typically does not recur after surgical removal. Lastly, it summarizes a phase 1 trial of a topical treatment (SM04554) for AGA, which appears to be safe, well-tolerated, and potentially efficacious in slowing hair loss and promoting hair growth.